ArticlePloS one2019
Novel mouse monoclonal antibodies specifically recognizing β-(1→3)-D-glucan antigen.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Detection of Polysaccharide Markers of Fungal Infections by Surface-Enhanced Raman Scattering and Machine Learning Methods.Biosensors · 2026Article
- β-Glucans,Journal of fungi (Basel, Switzerland) · 2026Review
- Antibody-drug conjugates for infectious and neglected tropical diseases: chemical design principles, target biology, and translational challenges.Frontiers in chemistry · 2026Review
- Pathogenic mucorales: Deciphering their cell wall polysaccharidome and immunostimulatory potential.Virulence · 2025Article
- Antifungal Innate Immunity.Advances in experimental medicine and biology · 2025Review
- β-1,6-Glucan plays a central role in the structure and remodeling of the bilaminate fungal cell wall.eLife · 2024Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Identification of a new DC-SIGN binding pentamannoside epitope within the complex structure ofCell surface (Amsterdam, Netherlands) · 2023Article
- Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19.International journal of molecular sciences · 2023Article
- Anti-glycan monoclonal antibodies: Basic research and clinical applications.Current opinion in chemical biology · 2023Review
- Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics.Journal of fungi (Basel, Switzerland) · 2023Review
- New Neutralizing Epitope Exposed on the Domain II of Tick-Borne Encephalitis Virus Envelope Glycoprotein E.Viruses · 2023Article
- Article
- ASCA-related antibodies in the blood sera of healthy donors and patients with colorectal cancer: characterization with oligosaccharides related toFrontiers in molecular biosciences · 2023Article
- Immunotherapies against human bacterial and fungal infectious diseases: A review.Frontiers in medicine · 2023Review
- Surfactant protein D inhibits growth, alters cell surface polysaccharide exposure and immune activation potential ofCell surface (Amsterdam, Netherlands) · 2022Article
- A Novel Monoclonal Antibody 1D2 That Broadly Inhibits Clinically ImportantJournal of fungi (Basel, Switzerland) · 2022Article
- Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.International journal of molecular sciences · 2022Review
- Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins ConferAntimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-(1→3)-D-Glucan is an essential component of the fungal cell wall. Mouse monoclonal antibodies (mAbs) against synthetic nona-β-(1→3)-D-glucoside conjugated with bovine serum albumin (BSA) were generated using hybridoma technology. The affinity constants of two selected mAbs, 3G11 and 5H5, measured by a surface plasmon resonance biosensor assay using biotinylated nona-β-(1→3)-D-glucan as the ligand, were approximately 11 nM and 1.9 nM, respectively. The glycoarray, which included a series of synthetic oligosaccharide derivatives representing β-glucans with different lengths of oligo-β-(1→3)-D-glucoside chains, demonstrated that linear tri-, penta- and nonaglucoside, as well as a β-(1→6)-branched octasaccharide, were recognized by mAb 5H5. By contrast, only linear oligo-β-(1→3)-D-glucoside chains that were not shorter than pentaglucosides (but not the branched octaglucoside) were ligands for mAb 3G11. Immunolabelling indicated that 3G11 and 5H5 interact with both yeasts and filamentous fungi, including species from Aspergillus, Candida, Penicillium genera and Saccharomyces cerevisiae, but not bacteria. Both mAbs could inhibit the germination of Aspergillus fumigatus conidia during the initial hours and demonstrated synergy with the antifungal fluconazole in killing C. albicans in vitro. In addition, mAbs 3G11 and 5H5 demonstrated protective activity in in vivo experiments, suggesting that these β-glucan-specific mAbs could be useful in combinatorial antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.